Molecular Formula | C10H14N2O |
Molar Mass | 178.23 |
Density | 1.06 g/mL at 25 °C (lit.) |
Melting Point | 23 °C (lit.) |
Boling Point | 296-300 °C (lit.) |
Flash Point | >230°F |
Water Solubility | >=10 g/100 mL at 23 C |
Vapor Presure | 0.0013mmHg at 25°C |
Appearance | Liquid |
Color | Clear colorless to yellow |
Merck | 14,6543 |
BRN | 5743 |
pKa | pKa 3.46(H2O,t =20) (Uncertain) |
Storage Condition | 2-8°C |
Refractive Index | n20/D 1.524(lit.) |
Physical and Chemical Properties | Slightly viscous liquid or crystalline solid |
Hazard Symbols | T - Toxic |
Risk Codes | R25 - Toxic if swallowed R36/37/38 - Irritating to eyes, respiratory system and skin. R23/24/25 - Toxic by inhalation, in contact with skin and if swallowed. |
Safety Description | S26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. S45 - In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.) S36/37/39 - Wear suitable protective clothing, gloves and eye/face protection. |
UN IDs | UN 2811 6.1/PG 3 |
WGK Germany | 3 |
RTECS | QS4375000 |
HS Code | 29333999 |
Hazard Class | 6.1(b) |
Packing Group | III |
Toxicity | LD50 i.p. in rats: 272 mg/kg (Goldenthal) |
This product is N,N-diethylnicotinamide. The content of C10H14N20 shall not be less than 98.5% (g/g).
The relative density of this product (General rule 0601) is 1.058~1.066 at 25°C.
The freezing point of this product (General 0613) is 22~24°C.
The refractive index of this product (General 0622) is 1.522-1.524 at 25°C.
Take 5.0g of this product, add water to dissolve and dilute it to 20ml, and measure it according to law (General rule 0631). The pH value should be 6.5~7.8.
take 2.5g of this product, add water to dissolve and dilute to 0902, the solution should be clear and colorless; If it is turbid, it should not be more concentrated compared with No. 1 turbidity standard solution (General Principles first method); in case of color development, it shall not be deeper in comparison with the yellow No. 1 Standard Colorimetric solution (General rules 0901 first method).
Take 5.0g of this product and check it according to law (General rule 0801). Compared with the control solution made of standard sodium chloride solution 7.0 ml, it should not be more concentrated (0.0014%).
take this product, add water to dissolve and dilute to make a solution containing about 4mg per 1ml as a test solution; Take 1ml for precision measurement, put it in a 100ml measuring flask, dilute it with water to the scale, as a control solution. According to the high performance liquid chromatography (General rule 0512) test, silica gel bonded with eighteen alkyl silane was used as the filler, methanol-water (30:70) was used as the mobile phase, and the detection wavelength was 263nm. The number of theoretical plates shall not be less than 2000 based on the calculation of nikethamide peak, and the separation degree between nikethamide peak and its adjacent impurity peak shall meet the requirements. 10ul of the test solution and the control solution were respectively injected into the human liquid chromatograph, and the chromatogram was recorded to 2 times of the retention time of the main component peak. If there are impurity peaks in the chromatogram of the test solution, the sum of each impurity peak area shall not be greater than 0.5 times (0.5%) of the main peak area of the control solution.
take 1.2g of this product, add 5ml of water and potassium permanganate titration solution (0.02mol/L) M l, shake, pink should not disappear within 2 minutes.
take this product 0.5g, add carbon disulfide 5ml, immediately shake observation, the solution should be clear.
take this product about 0.15g, precision weighing, add glacial acetic acid 10ml and crystal violet indicator liquid 1 drop, with perchloric acid titration solution (0.1 mol/L) titration to the solution is blue-green, and the result of the titration is corrected with a blank test. Each 1 ml of perchloric acid titration solution (0.1 mol/L) corresponds to 17.82mg of C10H14N20.
Central stimulant.
light shielding, sealed storage.
This product is a sterilized aqueous solution of nikethamide. Nikethamide (Cl0lH14N20) shall be 90.0% to 110.0% of the label weight.
This product is a clear colorless liquid.
take 2ml of this product with a volume pipette, put it in a 200ml measuring flask, use 0. Washing the inner wall of the pipette with 5% sulfuric acid solution, washing liquid and measuring flask, dilute with 0.5% sulfuric acid solution to the scale, shake well; Take appropriate amount with precision, dilute quantitatively with 0.5% sulfuric acid solution to prepare a solution containing about 20ug of nikethamide per lm l, and measure the absorbance at the wavelength of 263nm by UV-visible spectrophotometry (General rule 0401), the absorption coefficient of C10H14N20 was calculated to be 292.
Same as nikethamide.
(1)1.5ml0.375g (2) 2ml:0.5g
light shielding, closed storage.
EPA chemical substance information | information provided by: ofmpeb.epa.gov (external link) |
respiratory stimulant | Nikethamide is a commonly used clinical respiratory stimulant, which is relatively safe, the maintenance time in the body is short, and the small amount, intermittent and alternating administration is better after administration. Morphine-induced respiratory depression effect is better; Respiratory muscle paralysis caused by respiratory depression is invalid. Once the facial muscle spasm, limb twitching and other convulsive signs should be immediately discontinued or reduced. The use of nikethamide at the same time, should actively deal with the primary disease, oxygen, airway support, control infection and other measures, which is the fundamental and key to successful rescue. |
pharmacological effects | nikethamide can directly stimulate the medulla oblongata respiratory center, making breathing deepen and accelerate. It is also possible to activate the respiratory center reflexively by stimulating the chemoreceptors of the carotid sinus and aortic body, and to increase the sensitivity of the respiratory center to carbon dioxide. On the cerebral cortex, vascular motor center and spinal cord also have a weak Excitatory effect, no direct Excitatory effect on other organs, too large dose can cause convulsions. Nikethamide has the characteristics of mild action, large safety range and low toxicity. |
pharmacokinetics | good absorption, rapid onset of action, short duration of action, A single intravenous injection can only maintain the effect of 5 to 10 minutes, into the body after the rapid distribution to the body, the body metabolism of nicotinamide, and then be methylated into N-methyl nicotinamide by urine discharge. |
Clinical application | 1. For respiratory depression rescue Nikethamide is the most commonly used respiratory stimulant, can be used for a variety of causes of central respiratory depression, of which the morphine drug poisoning caused by respiratory inhibition effect is the best, inhalation of general anesthetics poisoning, the worst effect of barbiturate poisoning. 2. Treatment of hyperbilirubinemia for hyperbilirubinemia, hemolytic disease of the newborn, simple application of its efficacy is not as good as phenobarbital, but the combination of the two drugs can improve efficacy, and can reduce the side effects of phenobarbital. The usual dose of 0.1g/kg daily, divided into three oral. 3. Treatment of hiccup intramuscular injection treatment of hiccup with satisfactory results. Its mechanism of action may be due to the excitation of the respiratory center, so that breathing to deepen the acceleration, increase the activity of the diaphragm, to alleviate the spasm of the diaphragm, and the end of the hiccup. |
adverse reactions | common facial irritation, dysphoria, convulsion, Nausea Vomit, etc. In large doses, elevated blood pressure, palpitations, sweating, facial flushing, Vomit, tremors, arrhythmias, convulsions, and even Coma may occur. |
overdose | poisoning symptoms: restlessness, confusion, Nausea, Vomit, Head Pain, sweating, convulsions, shortness of breath, at the same time there may be elevated blood pressure, heart palpitations, arrhythmia, respiratory paralysis and death. treatment: (1) when convulsion occurs, benzodiazepines or small doses of thiopental sodium or phenobarbital sodium can be injected for control. (2) intravenous infusion of 10% glucose injection to promote excretion. (3) symptomatic treatment and supportive therapy were given. |
note | 1. Cerebral edema, tachycardia, hyperthyroidism, arrhythmia, heart disease, pheochromocytoma, bronchial asthma, ulcer disease, acute angina and pregnant women, acute porphyria. 2. No effect on respiratory muscle paralysis. 3. Blood pressure rise, tremor should be promptly discontinued. 4. Nikethamide should not be injected into artery, which may cause arterial spasm and thrombus. In the event of facial muscle spasm, limb twitching and other convulsive signs should be immediately discontinued or reduced. 5. Overdose can cause epileptic seizures, followed by Coma. Seizures can be controlled by intravenous benzodiazepines or small doses of thiopental. 6. With tannic acid, organic alkali salts and various metal salts, may produce precipitation; Alkali heating can be hydrolyzed, and remove the ethylenediamine group to generate nicotinic acid salt. 7. Artificial respiration and oxygen therapy should be used in combination. |
purpose | This product is a central stimulant, and is also used for poisoning of anesthetics and other central depressants. Rats were intraperitoneally injected with an LD50 of 272mg/kg. |
production method | nicotinyl diethylamine hydrochloride is formed from the condensation of nicotinic acid and diethylamine salt, and then it is passed through the middle and. |